Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials

BACKGROUND: The majority of clinical trials of first-line systemic treatments for hepatocellular carcinoma (HCC) used placebo or sorafenib as comparators, and there are limited data providing a cross comparison of treatments in this setting, especially for newly-approved immune checkpoint inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Yue, Zhi, Wei-Hua, Xu, Fei, Zhang, Chen-Bo, Huang, Xiao-Qian, Luo, Jian-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130040/
https://www.ncbi.nlm.nih.gov/pubmed/34040331
http://dx.doi.org/10.3748/wjg.v27.i19.2415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130040/
https://www.ncbi.nlm.nih.gov/pubmed/34040331
http://dx.doi.org/10.3748/wjg.v27.i19.2415

Ejemplares similares